Thrombotic and Fibrinolytic Abnormality in Nontraumatic Osteonecrosis of the Femoral Head.
10.4055/jkoa.2002.37.1.31
- Author:
Yong Chan HA
1
;
Kyung Hoi KOO
;
Sun Chul HWANG
;
Jang Rak KIM
;
Hyung Bin PARK
;
Sang Rim KIM
;
Kyung Min KIM
Author Information
1. Department of Orthopaedic Surgery, Gyeong-Sang National University School of Medicine, Chinju, Korea. khkoo@nongae.gsnu.ac.kr
- Publication Type:Original Article
- Keywords:
Femoral head;
Osteonecrosis;
Thrombophilia;
Hypofibrinolysis
- MeSH:
Antibodies, Anticardiolipin;
Antithrombin III;
Case-Control Studies;
Female;
Fibrinolysis;
Head*;
Humans;
Immunoglobulin M;
Lipoprotein(a);
Lupus Coagulation Inhibitor;
Male;
Osteonecrosis*;
Plasminogen;
Plasminogen Activators;
Protein C;
Protein S;
Thrombophilia;
Thrombosis;
Tissue Plasminogen Activator
- From:The Journal of the Korean Orthopaedic Association
2002;37(1):31-35
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study was performed to determine whether abnormalities of thrombosis and fibrinolysis are associated with nontraumatic osteonecrosis of the femoral head. MATERIALS AND METHODS: A case-control study was conducted in 24 patients with nontraumatic osteonecrosis of the femoral head. These patients were matched with 24 controls for gender, age (1-year range), and time of presentation (1-year range). The study included 19 men and 5 women, and the mean age of patients and controls was 46 years (range, 16-68 years). Eight patients had idiopathic osteonecrosis and the remaining 16 patients had secondary osteonecrosis. Protein C activity, protein C antigenicity, protein S activity, protein S antigenicity, antithrombin III, anticardiolipin antibody-Ig G, anticardiolipin antibody-Ig M, lupus anticoagulant, plasminogen, tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), and lipoprotein(a) were investigated. RESULTS: Protein C antigenecity and protein S antigenecity, which have been known to decrease in osteonecrosis patients, were increased in patients compared with those of controls (P<0.05). No significant differences were found in the levels of other thrombotic or fibrinolytic factors. In a subgroup of 16 patients with secondary osteonecrosis, the level of anticardiolipin antibody immunoglobulin M was greater than in the respective controls (P<0.05). CONCLUSION: The results of the current study suggest that abnormalities in the coagulation and fibrinolytic system are not associated with the pathogenesis of osteonecrosis of the femoral head.
